Gemtuzumab ozogamicin (GO), which consists of a CD33 antibody linked to a small molecule toxin, benefits some AML patients but not many others, leaving room for other CD33-targeted therapeutics. The gene discussed is CD33; the disease is acute myeloid leukemia.